To include your compound in the COVID-19 Resource Center, submit it here.

MacroGenics reports Phase Ib/II data of margetuximab plus Keytruda to treat gastric and gastroesophageal junction cancer

MacroGenics Inc. (NASDAQ:MGNX) reported data from 51 evaluable patients with relapsed or refractory advanced HER2-positive gastric and gastroesophageal junction cancer with disease

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE